Summary: In an ex-vivo mechanistic study of patients with type 2 diabetes after myocardial infarction, early empagliflozin was associated with reduced NLRP3 inflammasome activation and senescence markers in patient-derived macrophages compared with delayed or no treatment.
PICO Summary
| Element | Detail |
|---|---|
| Population | 66 patients with type 2 diabetes after acute myocardial infarction; CD14+ monocyte-derived macrophages studied ex vivo. |
| Intervention | Empagliflozin started at discharge (early), with macrophage and plasma sampling over 180 days. |
| Comparison | Empagliflozin delayed by 90 days, and no-EMPA periods within the same patients. |
| Outcome | Early empagliflozin associated with reduced NLRP3 priming (IL1β mRNA) and caspase-1 activity, lower ATP release, and stabilised TNFα, IL6, MCP1, CD80, and senescence markers (p21, IL8, BCL2). Plasma senescence markers (MMP9, OPN, Serpin E1) largely unchanged. Effects seen on ex-vivo inflammatory stimulation. |
Expert Commentary
This is laboratory mechanism, not a clinical-outcomes trial, and on those terms it is a careful and interesting piece of work. The recurrent-risk window of thirty to ninety days after infarction is real, and the hypothesis that starting empagliflozin early dampens NLRP3 inflammasome activity in patients’ own macrophages gives a plausible cellular story for benefits the class already shows clinically. My caution is about not letting an elegant mechanism masquerade as a treatment recommendation. The readouts are ex-vivo macrophage responses to an inflammatory stimulus in sixty-six patients, the plasma senescence markers largely did not move, and nothing here measures reinfarction, heart failure, or death. Association at the bench is several steps from patient benefit at the bedside. Can I use this with my patients? Only indirectly. I already start an SGLT2 inhibitor promptly in eligible post-infarct patients with type 2 diabetes on the strength of the outcome trials, and this adds mechanistic comfort to that timing rather than changing the decision. I would want a clinical trial with hard endpoints testing early versus delayed initiation before treating the timing effect as established.
References
Cliff CL, Shah MU, Ward JK, et al. Timing-dependent anti-inflammatory effects of empagliflozin in monocyte-derived macrophages from post-myocardial infarct patients with type 2 diabetes. Cardiovasc Diabetol. 2026;25(1):43. doi:10.1186/s12933-025-03042-7